Trump has a 'small personal financial interest' in hydroxycholorquine drugmaker. Allies have bigger stakes.


President Trump has been promoting the malaria and lupus drug hydroxychloroquine to treat COVID-19 "with all of the enthusiasm of a real estate developer," even as the medical experts on his coronavirus task force have repeatedly "warned against overselling a drug yet to be proved a safe remedy, particularly for heart patients," The New York Times reports. Some hospitals in Sweden stopped using hodroxycholoriquinine to treat the coronavirus due to adverse side effects, and the International Society of Antimicrobial Chemotherapy rejected a positive French study it had published on the drug, cited by Trump.
Dr. Anthony Fauci, the top U.S. infectious disease officials, has warned publicly and privately against promoting the drug absent studies showing its effectiveness, and "behind the scenes, career health officials have raised even stronger warnings about the risk to some Americans' heart health and other complications, but been warned not to publicly speak out and potentially contradict Trump," Politico reports. "Trump's focus on the drugs ... has increasingly warped his administration's response. Health officials have been told to prioritize the anti-malaria drugs over other projects that scientists believe have more potential to fight the outbreak." So...
"If hydroxychloroquine becomes an accepted treatment, several pharmaceutical companies stand to profit, including shareholders and senior executives with connections to the president," the Times reports. "Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine." Other top Trump donors, allies, golf buddies, and Cabinet officials also have various ties to hydroxychlorquine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
On the other hand, some hospitals in New York are using the drug to treat COVID-19, with mixed results. Senior administration officials tell Politico that Trump really believes hydroxychloroquine could end the COVID-19 pandemic. Trump has told associates Oracle founder Larry Ellison first pointed him to the drug, and TV personality Dr. Mehmet Oz, Rudy Giuliani, and trade adviser Peter Navarro have boosted his faith. "He thinks that it's the drug that's going to get everyone back to work," one Republican close to the White House told Politico, joking: "Do you have a supply?"
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
What are AI hallucinations?
The Explainer Artificial intelligence is known for making things up – and that can cause real damage
By Elizabeth Carr-Ellis, The Week UK Published
-
Marine Le Pen: will her conviction fuel the far-right?
Talking Point With National Rally framing their ex-leader as a political martyr, is French court ruling an own goal for democracy?
By Genevieve Bates Published
-
The rise of tiny cocktails
The Week Recommends From mini martinis to 'snaquiris', Gen Z are driving the trend for downsized drinks
By Irenie Forshaw, The Week UK Published
-
Are free trade zones and alliances the answer to Trump's tariffs?
Today's Big Question Temptation is to retaliate with trade barriers, but most agree nations should focus on targeted trade pacts and strengthening cooperation
By Harriet Marsden, The Week UK Published
-
Trump tariffs: five scenarios for the world's economy
The Explainer A US recession? A trade war with China? How 'Liberation Day' could realign the globe
By Harriet Marsden, The Week UK Published
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US Published
-
Elon Musk: has he made Tesla toxic?
Talking Point Musk's political antics have given him the 'reverse Midas touch' when it comes to his EV empire
By The Week UK Published
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
By Justin Klawans, The Week US Published
-
Trump's tariffs: is EU's retaliation the best move?
Today's Big Question Global US levy on steel and aluminium imports has the EU hitting back but the UK keeping options open
By Harriet Marsden, The Week UK Published
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
By Peter Weber, The Week US Published
-
Trade wars, explained
The Explainer Free trade is almost always good for any economy – so why is it so unpopular?
By The Week UK Published